Software revenue growth rate and customer retention metrics (net dollar retention, new logo wins among top 20 pharma)
Internal pipeline clinical trial readouts (SGR-1505 MALT1 inhibitor, SGR-2921 CDC7 inhibitor) and IND filings
New collaboration announcements with milestone payment structures and royalty terms
Quarterly cash burn rate and runway visibility given negative FCF profile
moderate - Software revenue shows resilience as pharma R&D budgets are relatively stable through cycles, but biotech customer segment (30-40% of software base) faces funding pressure during risk-off periods. Drug discovery collaborations can see delayed decision-making during economic uncertainty. Revenue declined 4.2% YoY likely reflecting biotech funding drought in 2024-2025 rather than core platform issues.
High sensitivity through customer funding dynamics. Rising rates compress biotech valuations and reduce venture/IPO funding availability, directly impacting software customer acquisition and retention among emerging biopharma. Company's own cash position ($300M+ estimated) benefits from higher yields on treasury holdings, partially offsetting operational losses. Valuation multiple contracts as risk-free rates rise (currently 3.4x P/S versus historical 8-10x range).
Technology obsolescence risk as generative AI models (AlphaFold3, ESM-3) democratize protein structure prediction, potentially commoditizing aspects of computational drug discovery
Clinical trial failure risk in internal pipeline could eliminate future royalty revenue stream and damage platform credibility
Regulatory pathway uncertainty for AI/ML-designed drug candidates may extend development timelines and increase costs
growth - Attracts biotech/healthcare growth investors betting on platform adoption inflection and pipeline optionality. Current 54.6% one-year decline reflects risk-off rotation from unprofitable growth names. Requires high risk tolerance given negative margins, cash burn, and binary clinical outcomes. Not suitable for value/income investors given no earnings, no dividends, and elevated valuation on sales basis despite compression.
Trend
-1.7% vs SMA 50 · -27.2% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $252.2M $250.9M–$254.3M | — | -$1.96 | — | ±12% | High6 |
FY2026(current) | $234.7M $191.8M–$303.1M | ▼ -7.0% | -$2.03 | — | ±50% | High6 |
FY2027 | $264.6M $247.1M–$277.7M | ▲ +12.8% | -$1.25 | — | ±41% | High5 |
INSTITUTIONAL OWNERSHIP
SDGR News
About
schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SDGR◀ | $11.95 | -5.31% | $893M | — | +2328.7% | -4035.9% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.30% | — | 50.3 | +342182.5% | -4078.5% | 1500 |